

FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE



**Personal information**

First name(s) / Surname(s) Ricciarda GALANDRINI  
Address(es) Department of Experimental Medicine  
Sapienza University of Rome  
Viale Regina Elena, 324  
00161 Rome - Italy  
Telephone(s) 06 49974085  
Fax(es) 06 4468448  
E-mail ricciarda.galandrini@uniroma1.it  
Nationality Italian  
Gender Female

**Occupational field** Pathology, Immunology and Immunopathology – SSD MED/04

**Work experience**

**Dates** November 2006 to present

**Occupation or position held** Full Professor of Pathology, Immunology

**Main activities and responsibilities** Research activity: principal investigator and project coordinator in the field of cellular and molecular immunology and immunopathology.  
Academic teaching activity, Immunology and Immunopathology - Medical School (Degree in Medicine and Surgery, Degree for Laboratory Technicians).  
Clinical activity: Medical Director, diagnosis of allergic diseases laboratory unit – Policlinico Umberto I

**Name and address of employer** Sapienza University of Rome, School of Medicine, Department of Experimental Medicine  
**Sector** Academic, research, teaching and clinical activity.

**Dates** November 2001 to 2006

**Occupation or position held** Associate Professor of Pathology, Immunology

**Main activities and responsibilities** Research activity: principal investigator and project coordinator in the field of cellular and molecular immunology and immunopathology.  
Academic teaching activity, Immunology and Immunopathology in the Medical School (Degree in Medicine and Surgery, Degree for Laboratory Technicians).  
Clinical activity: medical doctor in the laboratory of Immunology and Immunopathology – Policlinico Umberto I

**Name and address of employer** Sapienza University of Rome, School of Medicine, Department of Experimental Medicine  
**Sector** Academic, research, teaching and clinical activity.

**Dates** November 1998 to 2001

<b>Occupation or position held</b>	<b>Researcher of Pathology, Immunology</b>
<b>Main activities and responsibilities</b>	Research, academic teaching and student training.
<b>Name and address of employer</b>	Sapienza University of Rome, School of Medicine, Department of Experimental Medicine and Pathology
Sector	Academic, research, teaching and clinical activity.
<b>Education and Training</b>	
Title of qualification awarded	<b>Post-doctoral fellow</b>
Name and address of employer	Laboratory of Immunology directed by Dr. DA Cantrell, Imperial Cancer Research Fundation, London, UK
Dates	<b>1995 to 1997</b>
Title of qualification awarded	<b>PhD in Experimental Medicine-University of L'Aquila</b>
Name and type of organization providing education and training	Laboratory of Immunology directed by Prof. A Santoni, Department of Experimental Medicine, Sapienza University, Rome.
Dates	<b>1992-1996</b>
Title of qualification awarded	<b>Residency program in Internal Medicine – Specialist in Internal Medicine</b>
Name and type of organization providing education and training	Clinical Unit of Internal Medicine and Hematology and Laboratory of Hematology, University of Perugia, School of Medicine, Perugia, Italy.
Dates	<b>1982-1987</b>
Title of qualification awarded	<b>Medical Degree with honours</b>
Name and type of organization providing education and training	University of Perugia, School of Medicine, Perugia, Italy.
Scientific activity	<p>Dr. Galandrini research activity has been mainly conducted in the field of natural immunity and aimed at understanding the mechanisms underlying the NK cell anti-tumor effector functions. Research interests have been mainly focused on the characterization of the role of small G proteins and lipid-modifying enzymes in the regulation of Natural Killer (NK) cell functions with particular regard on endocytic trafficking of cytolytic machinery components and lytic granule exocytosis. Such studies added new insights on the molecular effectors involved in the regulation of discrete steps of cytotoxic function. More recently, she has been involved in study regarding the relationship between NK cells and tumor targeting therapeutic antibodies. Her studies firstly elucidated a molecular pathway contributing to the resistance to anti-tumor activity and highlighted how next generation mAbs may potentiate NK-mediated anti-tumor effector functions.</p> <p><b>Member of scientific societies:</b>  Italian Society of Immunology, Clinical Immunology and Allergy (SIICA)  Society for Natural Immunity</p>

## SCIENTIFIC PUBLICATIONS

### Peer reviewed of selected publications (from last ten years)- IF (impact factor da ISI WEB of Knowledge)

1. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFN $\gamma$  production. Capuano C, Pighi C, Molfetta R, Paolini R, Battella S, Palmieri G, Giannini G, Belardinilli F, Santoni A, **Galandrini R**. *Oncol Immunology* 2017 March; 6(3): e1290037. IF 7.64
2. Local allergic rhinitis in children: Novel diagnostic features and potential biomarkers. Zicari AM, Occasi F, Di Fraia M, Mainiero F, Porzia A, **Galandrini R**, Giuffrida A, Bosco D, Bertin S, Duse M. *Am J Rhinol Allergy*. 2016 Sep;30(5):329-34. doi: 10.2500/ajra.2016.30.4352. IF 1.96
3. Regulation of NKG2D Expression and Signaling by Endocytosis. Molfetta R, Quatrini L, Zitti B, Capuano C, Galandrini R, Santoni A, Paolini R. *Trends Immunol*. 2016 Sep 22. pii: S1471-4906(16)30119-3. IF 10.4
4. Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, **Galandrini R**, Cippitelli M, Santoni A, Paolini R. *Sci Signal*. 2015 Oct 27;8(400):ra108. doi: 10.1126/scisignal.aab2724. IF 7.4
5. The multifaceted role of PIP2 in leukocyte biology. Tuosto L, Capuano C, Muscolini M, Santoni A, **Galandrini R**. *Cell Mol Life Sci*. 2015 Dec;72(23):4461-74. IF 5.8
6. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells. Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, **Galandrini R**. *Cancer Res*. 2015 Oct 1;75(19):4097-108. doi: 10.1158/0008-5472.CAN-15-0781. IF 9.32
7. Treatment with icatibant in the management of drug induced angioedema. Bertazzoni G, Bresciani E, Cipollone L, Fante E, **Galandrini R**. *Eur Rev Med Pharmacol Sci*. 2015 Jan;19(1):149-53. IF 1.21
8. Phosphatidylinositol 4-phosphate 5-kinase  $\alpha$  and Vav1 mutual cooperation in CD28-mediated actin remodeling and signaling functions. Muscolini M, Camperio C, Porciello N, Caristi S, Capuano C, Viola A, **Galandrini R**, Tuosto L. *J Immunol*. 2015 Feb 1;194(3):1323-33. doi: 10.4049/jimmunol.1401643. IF 4.92
9. Serum resistin levels in children with primary snoring. Zicari AM, Cutrera R, Occasi F, Carbone MP, Cesoni Marcelli A, De Castro G, Indinnimeo L, Tancredi G, **Galandrini R**, Giuffrida A, Duse M. *Int J Immunopathol Pharmacol*. 2014 Jul-Sep;27(3):449-54. IF 2.05
- c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, **Galandrini R**, Santoni A, Paolini R. *Eur J Immunol*. 2014 Sep;44(9):2761-70. doi: 10.1002/eji.201444512. IF 4.17
10. Cancer-associated CD43 glycoforms as target of immunotherapy. Tuccillo FM, Palmieri C, Fiume G, de Laurentis A, Schiavone M, Falcone C, Iaccino E, **Galandrini R**, Capuano C, Santoni A, D'Armiento FP, Arra C, Barbieri A, Dal Piaz F, Venzon D, Bonelli P, Buonaguro FM, Scala I, Mallardo M, Quinto I, Scala G. *Mol Cancer Ther*. 2014 Mar;13(3):752-62. doi: 10.1158/1535-7163.MCT-13-0651. IF 5.68
11. Activation of Lymphocyte Cytolytic Machinery: Where are We? **Galandrini R**, Capuano C, Santoni A. *Front Immunol*. 2013 Nov 19;4:390. doi: 10.3389/fimmu.2013.00390. IF 5.69
12. Assessing the relationship between serum resistin and nasal obstruction in children with allergic rhinitis. Zicari AM, Occasi F, Cesoni Marcelli C, Lollobrigida V, Carbone MP, **Galandrini R**, Giuffrida A, Duse M. *Am J Rhinol Allergy*. 2013 Sep-Oct;27(5):e127-30. doi: 10.2500/ajra.2013.27.3944 IF 1.81
13. Phosphatidylinositol 4-phosphate 5-kinase  $\alpha$  activation critically contributes to CD28-dependent signaling responses. Muscolini M, Camperio C, Capuano C, Caristi S, Piccolella E, **Galandrini R**, Tuosto L. *J Immunol*. 2013 May 15;190(10):5279-86. doi: 10.4049/jimmunol.1203157. IF 4.92
14. PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, **Galandrini R**. *Blood*. 2012 Mar 8;119(10):2252-62. doi: 10.1182/blood-2010-12-324160. IF 10.45
15. NKG2A inhibits NKG2C effector functions of  $\gamma\delta$  T cells: implications in health and disease. Angelini DF, Zambello R, **Galandrini R**, Diamantini A, Placido R, Micucci F, Poccia F, Semenzato G, Borsellino G, Santoni A, Battistini L. *J Leukoc Biol*. 2011 Jan;89(1):75-84. doi: 10.1189/jlb.0710413. IF 4.28
16. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R\*, Paolini R\*. *J Immunol*. 2010 Apr 15;184(8):4170-7. doi: 10.4049/jimmunol.0903375. \* equal contribution IF 4.92
17. PI5KI-dependent signals are critical regulators of the cytolytic secretory pathway. Micucci F, Capuano C, Marchetti E, Piccoli M, Frati L, Santoni A, **Galandrini R**. *Blood*. 2008 Apr 15;111(8):4165-72. IF 10.45
18. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis. **Galandrini R**, Porpora MG, Stoppacciaro A, Micucci F, Capuano C, Tassi I, Di Felice A, Benedetti-Panici P, Santoni A. *Fertil Steril*. 2008 May;89(5):1490-6. IF 4.59
19. High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. Micucci F, Zingoni A, Piccoli M, Frati L, Santoni A, **Galandrini R**. *Exp Hematol*. 2006 Oct;34(10):1344-52. IF 2.47

Firmato  
Ricciarda Galandrini